Cargando…

Cellular and physical microenvironments regulate the aggressiveness and sunitinib chemosensitivity of clear cell renal cell carcinoma

Renal cell carcinoma (RCC) is the most predominant type of kidney cancer in adults and is responsible for approximately 85% of clinical cases. The tumor‐specific microenvironment includes both cellular and physical factors, and it regulates the homeostasis and function of cancer cells. Perirenal adi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagase, Kei, Akutagawa, Takashi, Rikitake‐Yamamoto, Mihoko, Morito, Sayuri, Futamata, Maki, Tobu, Shohei, Noguchi, Mitsuru, Toda, Shuji, Aoki, Shigehisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2021
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248239/ https://www.ncbi.nlm.nih.gov/pubmed/33512712 http://dx.doi.org/10.1002/path.5630

Ejemplares similares

Tissue-specific Physical and Biological Microenvironments Modulate the Behavior of Cervical Squamous Cell Carcinoma
por: Hanashima, Katsuyuki, et al.
Publicado: (2021)

The Association between Metabolic Syndrome and High-Stage Primary Urothelial Carcinoma of the Bladder
por: Nagase, Kei, et al.
Publicado: (2018)

Suture Granuloma Showing False-Positive Findings on FDG-PET
por: Takahara, Kohei, et al.
Publicado: (2013)

Iliac Artery-Uretero-Colonic Fistula Presenting as Gastrointestinal Hemorrhage and Hematuria: A Case Report
por: Kurata, Saya, et al.
Publicado: (2018)

Benzalkonium chloride induced corrosive balanoposthitis in a man requiring clean intermittent catheterization
por: Satoji, Yo, et al.
Publicado: (2021)

ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report
por: Kai, Keita, et al.
Publicado: (2022)

Pediatric cystine stone successfully treated by mini‐percutaneous nephrolithotripsy and antegrade ureteroscopy
por: Kakinoki, Hiroaki, et al.
Publicado: (2023)

A Case of Urethral Duplication Arising from the Posterior Urethra to the Scrotum with Urinary Stone in a 6-Year-Old Male
por: Mori, Kenichi, et al.
Publicado: (2014)

Two cases of nivolumab plus ipilimumab therapy for dialysis patients with advanced bone metastasis from renal cell carcinoma
por: Takahashi, Mika, et al.
Publicado: (2022)

Culture Models for Studying Thyroid Biology and Disorders
por: Toda, Shuji, et al.
Publicado: (2011)

Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma
por: Tsuchiya, Norihiko, et al.
Publicado: (2014)

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer
por: Alifrangis, C, et al.
Publicado: (2016)

Renoprotective effects of telmisartan after unilateral renal ablation in rats
por: Matsuo, Tomohiro, et al.
Publicado: (2013)

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer
por: Powles, T., et al.
Publicado: (2011)

Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer
por: Stewart, Grant D., et al.
Publicado: (2016)

Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment
por: Tada, Kouki, et al.
Publicado: (2022)

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
por: Shibasaki, Noboru, et al.
Publicado: (2015)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
por: Dufies, Maeva, et al.
Publicado: (2017)

Pharmacokinetic/Pharmacodynamic Analysis of a Hemodialyzed Patient Treated with 25 mg of Sunitinib
por: Noda, Satoshi, et al.
Publicado: (2012)

HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma
por: Maroto, P, et al.
Publicado: (2017)

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
por: Kontovinis, Loukas F, et al.
Publicado: (2009)

The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer
por: Powles, Thomas, et al.
Publicado: (2008)

Acute Acalculous Cholecystitis in Patients With Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Report of Two Cases
por: Furubayashi, Nobuki, et al.
Publicado: (2014)

Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
por: Pilskog, Martin, et al.
Publicado: (2017)

Overexpression of FZD1 is Associated with a Good Prognosis and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma
por: Peng, Qiang, et al.
Publicado: (2019)

TFE3‐PD‐L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma
por: Guo, Xudong, et al.
Publicado: (2020)

Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
por: Wei, Yuang, et al.
Publicado: (2021)

Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma
por: Song, Zhengshuai, et al.
Publicado: (2020)

Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
por: Eto, Masatoshi, et al.
Publicado: (2022)

Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients
por: Numakura, Kazuyuki, et al.
Publicado: (2018)

CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib
por: Haider, Masoom A., et al.
Publicado: (2017)

Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma
por: Dufies, Maeva, et al.
Publicado: (2018)

PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance
por: Feng, Chenchen, et al.
Publicado: (2021)

miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma
por: Park, Sang Eun, et al.
Publicado: (2022)

Clear cell carcinoid tumor of the distal common bile duct
por: Todoroki, Takeshi, et al.
Publicado: (2007)

Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population
por: Isaacsson Velho, Pedro, et al.
Publicado: (2018)

Correction to: PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance
por: Feng, Chenchen, et al.
Publicado: (2021)

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
por: Grünwald, Viktor, et al.
Publicado: (2023)

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
por: Xander, Nicolas S. H., et al.
Publicado: (2023)

Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma
por: Yuan, Huiyang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hs1eqor9i98oektklid5rr0s5b